electroCore to Participate at the 38th Annual Roth Conference
Rhea-AI Summary
electroCore (Nasdaq: ECOR) management will participate in the 38th Annual Roth Conference March 22–24, 2026, at the Ritz-Carlton in Laguna Niguel, California. CFO Joshua Lev will host one-on-one investor meetings. Investors can schedule via their Roth representative or by emailing investors@electrocore.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed action: NMTC (-3.84%), IINN (-3.60%), MODD (-0.95% in sector list but +3.74% in momentum scan), MYO (-0.21% in sector list and -5.12% in momentum scan), RBOT (+6.00%). With ECOR down 3.07% ahead of this neutral conference news, moves appear more stock-specific than purely sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | PTSD study collaboration | Positive | +10.2% | Announcement of PTSD study using gammaCore Sapphire with up to 40 adults. |
| Jan 20 | Prelim 2025 update | Positive | -3.6% | Preliminary 2025 results guiding to ~26% revenue growth and record sales. |
| Dec 02 | TAC-STIM performance data | Positive | -0.4% | Peer‑reviewed data showing significant performance and mood improvements with tVNS. |
| Nov 10 | Conference participation | Neutral | +1.3% | Announcement of participation at a Canaccord MedTech and digital health forum. |
| Nov 05 | Q3 2025 earnings | Positive | +23.2% | Record Q3 net sales, strong growth, and raised full‑year 2025 revenue guidance. |
ECOR has often reacted positively to clearly growth-focused or earnings updates, but product/clinical wins and neutral conference participation have produced mixed or muted moves.
Over the last few months, ECOR reported record Q3 2025 net sales and raised 2025 revenue guidance on Nov 5, 2025, which coincided with a strong +23.21% move. A subsequent preliminary 2025 update on Jan 20, 2026 guided to ~26% revenue growth but saw a modest -3.64% reaction. Clinical and research updates, including a PTSD study and TAC-STIM performance data, drove a mix of gains and slight declines. Prior conference participation on Nov 10, 2025 led to only a small positive move, suggesting today’s Roth appearance fits a non-catalytic pattern.
Regulatory & Risk Context
An effective S-3 resale registration dated Oct 3, 2025 covers up to 762,508 shares of common stock for selling stockholders. The company is not selling securities or receiving proceeds in connection with this registration, but it facilitates liquidity for existing holders.
Market Pulse Summary
This announcement highlights ECOR management’s participation in the 38th Annual Roth Conference from March 22–24, offering one-on-one meeting access but no new financial or clinical data. In recent months, the company reported strong revenue growth and notable clinical and performance-study updates with mixed market reactions. Investors monitoring this event typically focus on any subsequent presentations, updated guidance, or follow-on SEC filings that might emerge from the increased investor engagement.
Key Terms
bioelectronic medicine medical
AI-generated analysis. Not financial advice.
ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference March 22-24 at the Ritz-Carlton in Laguna Niguel, California. Joshua Lev, Chief Financial Officer, will host one-on-one meetings at the conference.
Investors attending this event who are interested in scheduling a meeting with management can do so by contacting their respective Roth representative, or by emailing investors@electrocore.com for more information.
About the Roth Capital Partners Conference
The Annual ROTH Conference is one of the largest in the nation for small-cap companies, combining company presentations, Q&A sessions and management 1-on-1 meetings. The format provides investors with the opportunity to hear from and meet with executive management from approximately 500 private and public companies in a variety of growth sectors. Roth’s award-winning Research Team identifies distinguished presenting companies across broad sectors, including consumer, energy, healthcare, industrial growth, metals & mining, sustainability, services, technology and more.
About electroCore, Inc.
electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Trvuaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
When will electroCore (ECOR) management attend the 38th Annual Roth Conference?
Who from electroCore (ECOR) will be available for investor meetings at the Roth Conference?
How can investors schedule a meeting with electroCore (ECOR) at the Roth Conference?
Where is the 38th Annual Roth Conference, where electroCore (ECOR) will participate, held?
Will electroCore (ECOR) provide a public presentation or only one-on-one meetings at the Roth Conference?
